INT2496

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 1979
Last Reported 2009
Negated 1
Speculated 0
Reported most in Abstract
Documents 32
Total Number 32
Disease Relevance 3.00
Pain Relevance 10.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Sult1b1) cytoplasm (Sult1b1)
Anatomy Link Frequency
median eminence 7
astrocytes 4
brain 2
cerebral cortex 2
ganglion 2
Sult1b1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Morphine 17 99.84 Very High Very High Very High
Dopamine 48 99.80 Very High Very High Very High
withdrawal 15 99.70 Very High Very High Very High
cerebral cortex 12 99.68 Very High Very High Very High
Hippocampus 3 99.28 Very High Very High Very High
narcan 12 99.16 Very High Very High Very High
opioid receptor 1 98.76 Very High Very High Very High
tetrodotoxin 23 98.52 Very High Very High Very High
antagonist 26 98.34 Very High Very High Very High
addiction 9 98.32 Very High Very High Very High
Disease Link Frequency Relevance Heat
Ganglion Cysts 32 99.68 Very High Very High Very High
Decapitation 5 97.30 Very High Very High Very High
Disease 5 95.80 Very High Very High Very High
Opiate Addiction 2 78.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The (+)-isomer produced no DOPA release.
Neg (no) Gene_expression (produced) of DOPA
1) Confidence 0.66 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.64
Peripheral administration of L-3,4-dihydroxyphenylalanine (L-DOPA) methylester increased extracellular levels of DOPA and dopamine (DA) in the rat striatum monitored by in vivo brain microdialysis.
Gene_expression (levels) of DOPA in brain associated with dopamine
2) Confidence 0.29 Published 1992 Journal Life Sci. Section Abstract Doc Link 1325018 Disease Relevance 0 Pain Relevance 0.38
Since the effects of morphine on the apomorphine-induced inhibition of DOPA accumulation were antagonized by naloxone, we suggest that the effects on striatal DOPA accumulation produced by morphine were mediated via opioid receptors and not directly via DA receptors.
Gene_expression (produced) of DOPA associated with narcan, opioid receptor and morphine
3) Confidence 0.25 Published 1979 Journal Eur. J. Pharmacol. Section Abstract Doc Link 456411 Disease Relevance 0 Pain Relevance 1.18
The Ca2+ channel blockers verapamil (100 microM) and Co2+ (4 mM) were effective in reducing the depolarization-induced DOPA synthesis.
Gene_expression (synthesis) of DOPA
4) Confidence 0.18 Published 1985 Journal Brain Res. Section Abstract Doc Link 2415215 Disease Relevance 0 Pain Relevance 0.23
On the other hand, tetrodotoxin (2 microM), a Na+ channel blocker, did not change the basal and K+-induced DOPA synthesis in the median eminence whereas it completely inhibited the veratridine-induced DOPA synthesis.
Gene_expression (synthesis) of DOPA in median eminence associated with tetrodotoxin
5) Confidence 0.14 Published 1985 Journal Brain Res. Section Abstract Doc Link 2415215 Disease Relevance 0 Pain Relevance 0.24
On the other hand, tetrodotoxin (2 microM), a Na+ channel blocker, did not change the basal and K+-induced DOPA synthesis in the median eminence whereas it completely inhibited the veratridine-induced DOPA synthesis.
Gene_expression (synthesis) of DOPA in median eminence associated with tetrodotoxin
6) Confidence 0.14 Published 1985 Journal Brain Res. Section Abstract Doc Link 2415215 Disease Relevance 0 Pain Relevance 0.24
The rate of dopamine biosynthesis was estimated by in vitro dihydroxyphenylalanine (DOPA) synthesis in the median eminence following incubation of rat hypothalamic slices with a DOPA decarboxylase inhibitor.
Gene_expression (synthesis) of DOPA in median eminence associated with dopamine
7) Confidence 0.14 Published 1985 Journal Brain Res. Section Abstract Doc Link 2415215 Disease Relevance 0 Pain Relevance 0.13
Depolarizing agents such as K+ and veratridine increased the synthesis rate of DOPA in the median eminence in a dose-dependent manner with a maximal synthesis rate obtained at concentrations of 50 mM and 50 microM, respectively.
Gene_expression (synthesis) of DOPA in median eminence
8) Confidence 0.14 Published 1985 Journal Brain Res. Section Abstract Doc Link 2415215 Disease Relevance 0 Pain Relevance 0.18
Removal of Ca2+ and addition of EGTA (1 mM) into the medium did not influence basal DOPA synthesis in the median eminence but blocked the K+- and veratridine-induced DOPA synthesis.
Gene_expression (synthesis) of DOPA in median eminence
9) Confidence 0.14 Published 1985 Journal Brain Res. Section Abstract Doc Link 2415215 Disease Relevance 0 Pain Relevance 0.22
Removal of Ca2+ and addition of EGTA (1 mM) into the medium did not influence basal DOPA synthesis in the median eminence but blocked the K+- and veratridine-induced DOPA synthesis.
Gene_expression (synthesis) of DOPA in median eminence
10) Confidence 0.14 Published 1985 Journal Brain Res. Section Abstract Doc Link 2415215 Disease Relevance 0 Pain Relevance 0.22
A23187 (10 microM), a Ca2+ ionophore, stimulated basal DOPA synthesis in the median eminence.
Gene_expression (synthesis) of DOPA in median eminence
11) Confidence 0.14 Published 1985 Journal Brain Res. Section Abstract Doc Link 2415215 Disease Relevance 0 Pain Relevance 0.24
Acute WIN (8 mg/kg; 1 h) increased DOPA synthesis in cortex (52%), hippocampus (51%), and cerebellum (56%) and decreased DOPA accumulation in striatum (31%).
Gene_expression (synthesis) of DOPA in striatum associated with hippocampus
12) Confidence 0.13 Published 2009 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 18709357 Disease Relevance 0 Pain Relevance 0.87
In the hypothalamus and cerebral cortex, clonidine (0.025-1 mg/kg, i.p.) decreased (18%-43%) and idazoxan (0.1-80 mg/kg, i.p.) increased (20%-73%) the synthesis of DOPA in a dose-dependent manner.
Gene_expression (synthesis) of DOPA in cerebral cortex associated with cerebral cortex and clonidine
13) Confidence 0.09 Published 1992 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 1353254 Disease Relevance 0.08 Pain Relevance 0.46
However, other agonists (oxymetazoline, azepexole, tramazoline, methoxamine) and antagonists (tolazoline, dihydroergotamine, phenoxybenzamine, propranolol) did not modify the synthesis of DOPA.
Gene_expression (synthesis) of DOPA associated with antagonist and agonist
14) Confidence 0.09 Published 1992 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 1353254 Disease Relevance 0.07 Pain Relevance 0.64
After treatment with reserpine (5 mg/kg, s.c., 18 h before decapitation) and depletion of noradrenaline, clonidine (0.5 mg/kg) continued to decrease (50%-55%) but idazoxan (20 mg/kg) failed to increase the synthesis of DOPA, which suggested the involvement of an alpha-auto-receptor mechanism.
Gene_expression (synthesis) of DOPA associated with noradrenaline, decapitation and clonidine
15) Confidence 0.09 Published 1992 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 1353254 Disease Relevance 0.10 Pain Relevance 0.55
Stimulation of DOPA synthesis in the superior cervical ganglion by veratridine.
Gene_expression (synthesis) of DOPA in superior cervical ganglion associated with ganglion cysts
16) Confidence 0.08 Published 1984 Journal J. Neurochem. Section Title Doc Link 6141219 Disease Relevance 0.37 Pain Relevance 0.13
Acute treatments of rats (not exposed to reserpine) with a wide variety of adrenoceptor agonists such as guanfacine 6, B-HT920, xylazine, bromoxidine (1 mg/kg) and antagonists such as yohimbine, phentolamine, prazosin (10 or 20 mg/kg) resulted in significant decreases (15%-55%) or increases (21%-99%) in the synthesis of DOPA in both brain regions.
Gene_expression (synthesis) of DOPA in brain associated with antagonist and agonist
17) Confidence 0.07 Published 1992 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 1353254 Disease Relevance 0.08 Pain Relevance 0.66
Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model.
Gene_expression (producing) of DOPA in astrocytes
18) Confidence 0.07 Published 1996 Journal Exp. Neurol. Section Title Doc Link 8635567 Disease Relevance 0 Pain Relevance 0.07
With future improvement in the gene transduction procedure for more efficient, sustained expression of the TH transgene in vivo, genetically engineered DOPA-producing astrocytes hold great promise as a tool to explore the potential of ex vivo gene therapy in Parkinson's disease.
Gene_expression (producing) of DOPA in astrocytes associated with disease
19) Confidence 0.07 Published 1996 Journal Exp. Neurol. Section Abstract Doc Link 8635567 Disease Relevance 0.10 Pain Relevance 0.06
DOPA production in the transduced astrocytes was largely independent of exogenous cofactor, and DOPA release into the medium was not influenced by addition of either KCl or tetrodotoxin or by removal of Ca2+ from the culture medium, indicating that the newly synthesized DOPA was constitutively released from the cells.
Gene_expression (synthesized) of DOPA in astrocytes associated with tetrodotoxin
20) Confidence 0.07 Published 1996 Journal Exp. Neurol. Section Abstract Doc Link 8635567 Disease Relevance 0 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox